A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK0869 [aprepitant] in the Maintenance of Antidepressant Effect in Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 10 May 2017
At a glance
- Drugs Aprepitant (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Merck & Co
- 31 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 01 Oct 2005 New trial record.